ArticlePLoS pathogens2022
Cross-protection against African swine fever virus upon intranasal vaccination is associated with an adaptive-innate immune crosstalk.
Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Public acceptance of policy measures to prevent and combat infectious diseases in pets: a systematic literature review.Frontiers in veterinary science · 2025Pooled it
- Distinct cytotoxic cell subsets underlie protective and non-protective immunity to African swine fever virus.Emerging microbes & infections · 2026Article
- Limited cross-protection induced by live attenuated ASF vaccines emphasizes caution for field use.Emerging microbes & infections · 2026Article
- MGF110-2L deletion prevents IFN-I and inflammatory response, resulting in partial attenuation and protection against virulent ASFV.Journal of virology · 2026Article
- Correlates of protection against African swine fever virus identified by a systems immunology approach.eLife · 2026Article
- Adjuvant-induced macrophage activation compromises BA71ΔCD2-mediated protection against African swine fever virus.NPJ vaccines · 2026Article
- Live-vectored antigen cocktail confers protection against African swine fever virus (ASFV) Georgia 2007/1 challenge.NPJ vaccines · 2026Article
- African swine fever virus L11L interferes with antiviral responses by targeting the IRF3 and PKR.Cellular and molecular life sciences : CMLS · 2025Article
- African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly.Journal of virology · 2025Article
- A Mutant of Africa Swine Fever Virus Protein p72 Enhances Antibody Production and Regulates the Production of Cytokines.Viruses · 2025Article
- Molecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs.Veterinary sciences · 2025Article
- InactivatedFrontiers in immunology · 2025Article
- Transcriptome profiles of organ tissues from pigs experimentally infected with African swine fever virus in early phase of infection.Emerging microbes & infections · 2024Article
- Article
- Article
- Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.Journal of virology · 2024Article
- Single-cell analysis reveals lasting immunological consequences of influenza infection and respiratory immunization in the pig lung.PLoS pathogens · 2024Article
- Article
- Article
- Primary nasal viral infection rewires the tissue-scale memory response.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) is causing a worldwide pandemic affecting the porcine industry and leading to important global economic consequences. The virus causes a highly lethal hemorrhagic disease in wild boars and domestic pigs. Lack of effective vaccines hampers the control of virus spread, thus increasing the pressure on the scientific community for urgent solutions. However, knowledge on the immune components associated with protection is very limited. Here we characterized the in vitro recall response induced by immune cells from pigs intranasally vaccinated with the BA71ΔCD2 deletion mutant virus. Vaccination conferred dose-dependent cross-protection associated with both ASFV-specific antibodies and IFNγ-secreting cells. Importantly, bulk and single-cell transcriptomics of blood and lymph node cells from vaccinated pigs revealed a positive feedback from adaptive to innate immunity. Indeed, activation of Th1 and cytotoxic T cells was concomitant with a rapid IFNγ-dependent triggering of an inflammatory response characterized by TNF-producing macrophages, as well as CXCL10-expressing lymphocytes and cross-presenting dendritic cells. Altogether, this study provides a detailed phenotypic characterization of the immune cell subsets involved in cross-protection against ASFV, and highlights key functional immune mechanisms to be considered for the development of an effective ASF vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.